Literature DB >> 35016028

LTK fusions: A new target emerges in non-small cell lung cancer.

Alissa J Cooper1, Lecia V Sequist1, Ted W Johnson2, Jessica J Lin3.   

Abstract

Identification of targetable fusions as oncogenic drivers in non-small cell lung cancer has transformed its diagnostic and therapeutic paradigm. In a recent article in Nature, Izumi et al. report the discovery of CLIP1-LTK fusion as a novel oncogenic driver in lung cancer, targetable using the ALK tyrosine kinase inhibitor lorlatinib.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35016028      PMCID： PMC9574472          DOI： 10.1016/j.ccell.2021.12.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   38.585


  10 in total

1.  Leukocytes express a novel gene encoding a putative transmembrane protein-kinase devoid of an extracellular domain.

Authors:  Y Ben-Neriah; A R Bauskin
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

2.  High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.

Authors:  Ryma Benayed; Michael Offin; Kerry Mullaney; Purvil Sukhadia; Kelly Rios; Patrice Desmeules; Ryan Ptashkin; Helen Won; Jason Chang; Darragh Halpenny; Alison M Schram; Charles M Rudin; David M Hyman; Maria E Arcila; Michael F Berger; Ahmet Zehir; Mark G Kris; Alexander Drilon; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2019-04-26       Impact factor: 12.531

Review 3.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

4.  The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.

Authors:  Hiroki Izumi; Shingo Matsumoto; Jie Liu; Kosuke Tanaka; Shunta Mori; Kumiko Hayashi; Shogo Kumagai; Yuji Shibata; Takuma Hayashida; Kana Watanabe; Tatsuro Fukuhara; Takaya Ikeda; Kiyotaka Yoh; Terufumi Kato; Kazumi Nishino; Atsushi Nakamura; Ichiro Nakachi; Shoichi Kuyama; Naoki Furuya; Jun Sakakibara-Konishi; Isamu Okamoto; Kageaki Taima; Noriyuki Ebi; Haruko Daga; Akira Yamasaki; Masahiro Kodani; Hibiki Udagawa; Keisuke Kirita; Yoshitaka Zenke; Kaname Nosaki; Eri Sugiyama; Tetsuya Sakai; Tokiko Nakai; Genichiro Ishii; Seiji Niho; Atsushi Ohtsu; Susumu S Kobayashi; Koichi Goto
Journal:  Nature       Date:  2021-11-24       Impact factor: 69.504

5.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Authors:  Ted W Johnson; Paul F Richardson; Simon Bailey; Alexei Brooun; Benjamin J Burke; Michael R Collins; J Jean Cui; Judith G Deal; Ya-Li Deng; Dac Dinh; Lars D Engstrom; Mingying He; Jacqui Hoffman; Robert L Hoffman; Qinhua Huang; Robert S Kania; John C Kath; Hieu Lam; Justine L Lam; Phuong T Le; Laura Lingardo; Wei Liu; Michele McTigue; Cynthia L Palmer; Neal W Sach; Tod Smeal; Graham L Smith; Albert E Stewart; Sergei Timofeevski; Huichun Zhu; Jinjiang Zhu; Helen Y Zou; Martin P Edwards
Journal:  J Med Chem       Date:  2014-06-03       Impact factor: 7.446

6.  Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.

Authors:  Carsten Müller-Tidow; Sven Diederichs; Etmar Bulk; Thorsten Pohle; Björn Steffen; Joachim Schwäble; Sylvia Plewka; Michael Thomas; Ralf Metzger; Paul M Schneider; Christian H Brandts; Wolfgang E Berdel; Hubert Serve
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

Review 7.  Lung cancer.

Authors:  Alesha A Thai; Benjamin J Solomon; Lecia V Sequist; Justin F Gainor; Rebecca S Heist
Journal:  Lancet       Date:  2021-07-14       Impact factor: 79.321

8.  Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Authors:  Justin F Gainor; Diane Tseng; Satoshi Yoda; Ibiayi Dagogo-Jack; Luc Friboulet; Jessica J Lin; Harper G Hubbeling; Leila Dardaei; Anna F Farago; Katherine R Schultz; Lorin A Ferris; Zofia Piotrowska; James Hardwick; Donghui Huang; Mari Mino-Kenudson; A John Iafrate; Aaron N Hata; Beow Y Yeap; Alice T Shaw
Journal:  JCO Precis Oncol       Date:  2017-08-16

9.  ALK-activating homologous mutations in LTK induce cellular transformation.

Authors:  J Devon Roll; Gary W Reuther
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

Review 10.  Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.

Authors:  Mathieu Chevallier; Maxime Borgeaud; Alfredo Addeo; Alex Friedlaender
Journal:  World J Clin Oncol       Date:  2021-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.